The Global 'Renal Biomarkers Market" is expected to grow with a CAGR during the forecast period (2022-2029).
The renal biomarkers are the biomarkers that help to diagnose or identify the patients at risk of developing kidney diseases, by measuring their blood or urine levels. They are commonly released in acute or chronic kidney injuries, which are characterized by the rapid or gradual loss of kidney function resulting in serious clinical implications.
The global renal biomarkers market growth is driven by the increasing cases of kidney failures or disorders, growing prevalence of cardiac diseases, blood pressures, and diabetes are majorly driving the market.
The advancements in the field of genetic technology will drive the market growth
Advancements in the field of genetic technology during the last decade have enlightened people's knowledge regarding genetic regulatory pathways related to renal biomarkers. Due to rapid advances in genomic technologies, genetics analysis has become essential in clinical practice and research. Moreover, with the development of computer technology, renal biomarkers testing has become widely accessible and feasible to perform, even in small-sized laboratories. Recent advances in genetics have created opportunities to study kidney disease in a variety of platforms, applied to human populations. Renal biomarkers can also be integrated into genetic-level technological advancements for the detection, diagnosis, and treatment of kidney diseases. These rapid advances in genetics led to the development of more advanced renal biomarkers for treating kidney diseases, which ultimately drives the market.
Chronic kidney disease (CKD) is a major risk multiplier for cardiovascular disease, diabetes, hypertension, inflammatory disease of the kidney (glomerulonephritis), and aging. World Kidney Day, a global awareness campaign, estimated that 10% of the global population is affected by chronic kidney disease. According to the Centers for Disease Control and Prevention (CDC), more than 26 million Americans are affected by chronic kidney disease. Chronic kidney disease leads to end-stage renal disease (ESRD), if not treated. It was estimated by the National Kidney Foundation in 2015 that about 468,000 ESRD affected patients were on dialysis in the U.S.
Issues related to regulatory and reimbursement systems are likely to hamper the market growth
However, hard regulations by the FDA and EMA on the quality of renal biomarkers and lack of reimbursement by the government are hampering the growth of the market in the forecast period.
COVID‐19 is a very high transmission infectious disease with a variable prognosis in the general population. According to a research article by Claudia Benedetti et al., published in Frontiers in Medicine Journal 2020, the study results indicate that patients with kidney disease could represent a risk factor in elderly patients for a more severe disease course. COVID-19 infects the kidneys and may induce acute kidney injury.
As per Johns Hopkins University, some people with COVID-19 showed signs of kidney damage, and even those who had no underlying kidney problems before were infected with the coronavirus. Moreover, about 30% of patients hospitalized with COVID-19 in New York and China developed moderate or severe kidney injury. In patients with COVID-19, signs of kidney problems include abnormal blood work and high levels of protein in the urine, which may lead to kidney damage in some cases and require dialysis. Thus the pandemic is driving the growth of the market in the forecast period.
The functional biomarker segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)
The functional biomarker has the largest market share in the forecast period. Chronic kidney disease (CKD) has become a public health problem. According to the National Institute of Diabetes, Digestives, and Kidney Diseases, the overall prevalence of CKD in the general population is approximately 14%, and around 6,61,000 Americans have kidney failure. Currently, the diagnosis of CKD is made by the testing of levels of serum creatinine (SCr). The serum creatinine, a functional biomarker, dominates the market for renal biomarkers, owing to the high prevalence rate of CKD and the high presence and knowledge of serum creatinine biomarkers.
North America region holds the largest market share of global Renal Biomarkers Market
North America currently dominates the market for renal biomarkers, and it is expected to continue its stronghold for a few more years. In the North American region, the United States holds the largest market share. In the past decade, there was a significant increase in the number of USFDA-approved drug labels containing information on molecular biomarkers. Almost every pharmaceutical company has been developing molecular biomarker programs, either through partnerships or through other ventures.
Molecular biomarkers are expected to be identified and validated in drug development and used to support the approval of drug products. Such drug approvals are helping the renal biomarkers market grow in the United States.
The renal biomarkers market is highly competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Abbott Laboratories, BioPorto Diagnostics AS, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Pacific Biomarkers, and BioMérieux, Beckman Coulter (Danaher Corporation, Randox Laboratories Ltd, and Siemens Healthineers, Alere Inc. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the renal biomarkers market globally.
Thermo Fisher Scientific Inc.
Overview: Thermo Fisher Scientific Inc. develops, manufactures and sells a range of products. The Company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
PlexMark 3 Renal Biomarker Panel: Monitoring the profile of cytokines, chemokines, and receptor levels in the urine of renal transplant patients may be a noninvasive way to perform cost-effective research studies on renal damage. Recent studies have profiled levels of three analytes: monokine induced by interferon-gamma (MIG), interferon-inducible protein 10 (IP-10), and osteoprotegerin (OPG) in urine samples and show promise as important markers of renal dysfunction. The IP-10, MIG, and OPG triplex assay system is a research tool that may be useful in the development and research studies in the area of cryptic occurrence of acute kidney injury.